CENTESSA PHARMACEUTICALS PLC
Last · —$40.500.00 (0.00%)live · yahoo · 2h ago
Market cap$6.27B—
P/E · TTM—fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
| Revenue | $15.0M |
|---|---|
| Operating income | $-139.2M |
| Net income | $-131.4M |
| Free cash flow | $-138.4M |
| Operating margin | -928.1% |
| Net margin | -875.8% |
| Return on equity | -43.6% |
| Period | TTM 2025-09-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-31
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 206.4%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -1316.9%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -1292.1%
- Cash Runway Low — Cash runway ~0.3 years
- Accumulated Deficit High — Accumulated deficit / equity 228%
- Rd Intensity High — R&D/Revenue 1148.2%
Press & signals
- GlobeNewswire
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales